linjc16/ctgov huggingface dataset:
Buccal and Palatal Bone Thickness and Marginal Bone Changes Implants

Study Overview
=================
Brief Summary
-----------------
The primary outcome of the study was the vertical variation of peri-implant buccal and palatal bone level from implant placement (T0) to uncovering stage (3 months later - T1)

Detailed Description
-----------------
despite various recommendations, there is insufficient evidence to set a threshold for minimal buccal bone thickness necessary to ensure peri-implant marginal bone stability and optimal aesthetic outcomes. Therefore, the aim of the present multi-centre prospective study was to investigate the influence of buccal and palatal bone thickness at the time of implant placement on peri-implant bone remodeling during the submerged healing period, with a strict control of possible confounding factors.

Official Title
-----------------
Influence of Buccal and Palatal Bone Thickness on Post-surgical Marginal Bone Changes Around Implants Placed in Posterior Maxilla

Conditions
-----------------
Bone Implant; Complications

Intervention / Treatment
-----------------
* Procedure: implant insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years; no smokers; no history of periodontal disease; healed bone crest (at least six months after tooth extraction); crestal bone height ≥8 mm; crestal bone with a minimum bucco-palatal width of 6 mm with no concomitant or previous bone augmentation procedures. Exclusion Criteria: absolute contraindications to implant surgery immunological or genetic disorders; uncontrolled diabetes (HBA1c > 7.5%); present or past treatment with anti resorptive drugs; oncologic patients; history of head or neck radiotherapy; alcohol or drugs abuse; final insertion torque > 50 Ncm.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| maxillary group<br>implant insertion | Procedure: implant insertion<br>* bone level dental implant insertion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peri-implant bone changes in width buccal | measurement after implant site preparation with a caliper | three months after surgery | 
| peri-implant bone changes in width palatal | measurement after implant site preparation with a caliper | three months after surgery | 
| peri-implant bone changes in height buccal | measurement after implant insertion with a probe | three months after surgery | 
| peri-implant bone changes in height palatal | measurement after implant insertion with a probe | three months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
implant, peri-implant bone remodeling, posterior maxilla, bone thickness
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema

Study Overview
=================
Brief Summary
-----------------
8 years after the establishment of the therapeutic education program and 14 years after the creation of the National Reference Center for Angioedemas (CREAK), it is necessary to make an inventory in 2021 on the disease experienced by the patient with an assessment the needs and expectations of HAE patients. This assessment would make it possible to see the evolution of these needs and to adjust the price for the overall cost of children and adults in France. It may also allow a comparison of the requests expressed during a similar survey in another French-speaking region such as Quebec. Main objective is to know the needs and the current satisfaction of the needs, with regard to the disease and the treatment of the targeted patients of hereditary angioedema (HAE)

Official Title
-----------------
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema

Conditions
-----------------
Hereditary Angioedema

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with HAE with or without C1 inhibitor deficiency Patient over 15 or parents of a child under 15 with HAE Exclusion Criteria: Patient opposed to the use of their data or refusing to answer the questionnaire Adult patients protected by law
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| angiodema hereditary patients<br>Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire | Other: questionnaire<br>* electronic questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the needs and the current satisfaction of the needs, with regard to the disease and the treatment of patients with hereditary angioedema (HAE) | questionnaire To know the needs and the current satisfaction of the needs, with regard to the disease and the treatment of patients with hereditary angioedema (HAE) | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparaison of results with quebec | Comparison of the results of the French questionnaire, only the questions adapted from the Quebec questionnaire, with the results of the Quebec survey conducted by Jean-Nicolas Boursiquot in 2018. | baseline |
Red Cell Distribution Width and Mortality in Adult Pneumonia Patients

Study Overview
=================
Brief Summary
-----------------
Abstract Pneumonia is a leading cause of severe morbidity and mortality among adults. During the last two decades, several scores were developed to evaluate the probability of morbidity and mortality among patients with community acquired pneumonia (CAP), such as the PORT score and the CURB65. Recently, several studies showed that elevated Red Cell Distribution Width (RDW) could be used as a prognostic tool for predicting severe morbidity and mortality among patients with cardiac diseases. RDW is a quantitative measure for red blood cell (RBC) size variability. Recent studies have suggested that high levels of RDW are in association with higher mortality among cardiovascular patients. RDW has not yet been studied as a prognostic sign in CAP. The goal of this study is to examine the role of RDW as a prognostic factor for severe morbidity and mortality among patients who were hospitalized with CAP , independently to Hemoglobin levels, renal function and inflammatory markers.

Conditions
-----------------
Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients 18 years and older, hospitalized due to pneumonia between 2005-2010. All patients must have RDW values. - Exclusion Criteria: under 18 no RDW value The primary cause of hospitalization was not pneumonia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RDW, pneumonia, mortality, prognostic factor
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
Bazedoxifene/Conjugated Estrogens (BZA/CE) is an investigational drug that is being developed for treatment of menopause. The purpose of this trial is to compare a new manufacturing process for making BZA/CE to the current process by assessing the way it is absorbed into the blood.

Official Title
-----------------
An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Bazedoxifene/Conjugated Estrogens (Premarin Current Process) And Bazedoxifene/Conjugated Estrogens (Premarin New Process) In Healthy Postmenopausal Women

Conditions
-----------------
Menopause

Intervention / Treatment
-----------------
* Drug: Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women aged 35 to 70 years Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight greater than or equal to 50 kg Healthy as determined by the investigator on the basis of medical history, physical examination, breast and gynecologic examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). Exclusion Criteria: Any clinically important active condition of gynecologic, cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. History or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies. History of any clinically important drug allergy to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs).

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PK results |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postmenopausal
Intraoperative Norepinephrine Versus Fresh Frozen Plasma in Patients Undergoing HIPEC to Reduce Renal Insult

Study Overview
=================
Brief Summary
-----------------
comparing the effect of low dose norepinephrine infusion versus fresh frozen plasma in patients undergoing HIPEC to reduce renal insult

Detailed Description
-----------------
To compare the efficacy of maintaining intraoperative hemodynamic stability through infusing low dose norepinephrine versus fresh frozen plasma in patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy in cancer patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

Official Title
-----------------
Intraoperative Norepinephrine Versus Fresh Frozen Plasma in Patients Undergoing HIPEC to

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: Norepinephrine
* Biological: Fresh frozen plasma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I and II World Health Performance Status ≤2 scheduled for CRS/HIPEC operations Exclusion Criteria: patient's refusal allergy to any of the used drugs impaired renal or liver functions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fresh frozen plasma<br>early administration of fresh frozen plasma | Biological: Fresh frozen plasma<br>* early administration of fresh frozen plasma<br>* Other names: Blood products;|
| Experimental: Low dose norepinephrine<br>low dose epinephrine 5 mic/kg/hr | Drug: Norepinephrine<br>* 5 mic/kg/hr norepinephrine<br>* Other names: low dose norepinephrine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal insult | Creatinine level increase 0.3 mg/dl above preoperative baseline | 24 hours |
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Study Overview
=================
Brief Summary
-----------------
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

Official Title
-----------------
The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder

Conditions
-----------------
Schizophrenia, Psychotic Disorders, Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: Sibutramine


Participation Criteria
=================
Eligibility Criteria
-----------------
Eligibility Criteria: You must be between the ages of 18 and 65. If you have reached your 66th birthday, you will not be able to participate. You must have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder and be taking olanzapine. You must be able to visit the doctor's office as scheduled for the next 4 months. Exclusion Criteria: You have a history of an illness that would cause weight loss or gain in the near future. You have taken remoxipride within the past 6 months. You are allergic to olanzapine or Anti-obesity Agent. You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke. You have a serious medical illness, such as heart, liver, or kidney disease. You are pregnant or breast feeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sibutramine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizoaffective disorder, schizophreniform disorder, bipolar I disorder
Health Services Implications of a Teledermatology Consult System

Study Overview
=================
Brief Summary
-----------------
We have previously shown (IIR 95-045) that teledermatology, using store and forward technology, can result in reliable and accurate diagnostic outcomes when compared to clinic-based dermatology consultations. This investigation builds on that fundamental diagnostic information by assessing the health services implications of a teledermatology consult system.

Detailed Description
-----------------
Background: We have previously shown (IIR 95-045) that teledermatology, using store and forward technology, can result in reliable and accurate diagnostic outcomes when compared to clinic-based dermatology consultations. This investigation builds on that fundamental diagnostic information by assessing the health services implications of a teledermatology consult system. Objectives: To investigate health services outcomes related to teledermatology implementation. Outcomes of interest were time to diagnosis and treatment initiation, the proportion of patients that avoided the need for a clinic-based encounter, and an economic analysis. Methods: Patients referred from the primary care clinics to the dermatology consult service were randomized to either usual care or a teledermatology consultation. A usual care consultation consisted a conventional text-based electronic consult request. A teledermatology consultation included digital images and a standardized history, in addition to the electronic text-based consult. Consultant dermatologists, reviewing the consult requests for both modalities, decided when, and if, a referral required a clinic-based evaluation. Status: Final report has been prepared and is in the review process at this time.

Official Title
-----------------
Health Services Implications of a Teledermatology Consult System

Conditions
-----------------
Teledermatology

Intervention / Treatment
-----------------
* Procedure: Teledermatology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients referred to Dermatology Consult Service. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Arm 1<br> | Procedure: Teledermatology<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Cardiovascular Diseases in HIV-infected Subjects (HIV-HEART Study)

Study Overview
=================
Brief Summary
-----------------
Human immunodeficiency virus (HIV) infection has been associated with a variety of cardiovascular diseases. Even most industrialised countries exhibit a growing and aging population of HIV-infected patients in the majority treated with antiretroviral drugs, the investigators still do not know much about the impact of cardiovascular diseases in this group of patients. The present study is an ongoing trial that was conducted as a prospective and multicentre survey, being schemed to analyse the frequency and clinical course of cardiac disorders in HIV-infected patients.

Conditions
-----------------
Detection of Frequency, Severity and Progression of Cardiovascular Diseases in Patients With HIV-infection., Effect on Cardiovascular Risk and Life Quality by Age, Gender, Classic Cardiovascular Risk Factors,, HIV-specific Cardiovascular Risk Factors, Cardiovascular Medication, Antiretroviral Medication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Known HIV-infection Outpatients Written informed consent Exclusion Criteria: ● Acute cardiovascular disease or unstable hemodynamic status in the three weeks before inclusion • Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV-infected Outpatients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of cardiovascular diseases | Prevalence of cardiovascular diseases including coronary artery disease, congestive heart failure, peripheral arterial disease, cerebrovascular events, and valvular diseases. |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of cardiovascular disorders | Prevalence of cardiovascular disorders determined by electrocardiography, exercise testing, echocardiography, blood samples. |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac Diseases • HIV-Infection • AIDS • Antiretroviral Therapy
Metabolic Study of Concentric and Eccentric Muscle Training

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the metabolic and anti-inflammatory effects of eccentric endurance exercise and to compare them with those of concentric exercise in healthy sedentary individuals.

Detailed Description
-----------------
Physical exercise decreases the risk of obesity, diabetes mellitus, and cardiovascular disease. Skeletal muscle can be exercised by two ways: Concentric contraction is defined as active shortening of muscles, e.g. by stepping upwards, whereas eccentric muscle contraction is defined as active resistance to stretching, e.g. by stepping downwards. Although the effects of exercise (i.e. the combination of concentric and eccentric muscle contraction) on metabolic parameters have been extensively investigated, there are no data on the specific metabolic effects of concentric versus those of eccentric muscle work in humans. Comparison(s): Metabolic and anti-inflammatory effects of eccentric endurance exercise (i.e. stepping upwards), compared to metabolic and anti-inflammatory effects of concentric exercise (i.e. stepping downwards).

Conditions
-----------------
Lipid Metabolism, Insulin Resistance, Inflammation

Intervention / Treatment
-----------------
* Behavioral: physical training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy men and women age over 30 years Exclusion Criteria: previous systematic endurance training (≥3 times per week ≥30 min) body mass index >30 kg/m2 heavy smoking (>20 cigarettes per day) regular alcohol consumption >60g per day established musculoskeletal disease history of cardiovascular disease diabetes mellitus unwillingness to stay in the area for the whole study period

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: physical training|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic and anti-inflammatory effects induced by eccentric muscle exercise. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic and anti-inflammatory effects induced by concentric muscle exercise. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise, lipid metabolism, lipoproteins, insulin resistance, inflammation